Multidrug-resistant to extensively drug resistant tuberculosis: what is next?
dc.contributor.author | Jain, Amita | en_US |
dc.contributor.author | Dixit, Pratima | en_US |
dc.date.accessioned | 2008-11-12 | en_US |
dc.date.accessioned | 2009-06-01T14:38:25Z | |
dc.date.available | 2008-11-12 | en_US |
dc.date.available | 2009-06-01T14:38:25Z | |
dc.date.issued | 2008-11-12 | en_US |
dc.description | 76 references. | en_US |
dc.description.abstract | Drug resistant tuberculosis is a man made problem. While tuberculosis is hundred percent curable, multidrug resistant tuberculosis (MDR-TB) is difficult to treat. Inadequate and incomplete treatment and poor treatment adherence has led to a newer form of drug resistance known as extensively drug resistant tuberculosis (XDR-TB). XDR-TB is defined as tuberculosis caused by Mycobacterium tuberculosis strain, which is resistant to at least rifampicin and isoniazid among the first line anti tubercular drugs (MDR-TB) in addition to resistance to any fluroquinolones and at least one of three injectable second line anti tubercular drugs i.e. amikacin, kanamycin and/or capreomycin. Mismanagement of tuberculosis paves the way to drug resistant tuberculosis. Emergence of XDR-TB is reported world wide. Reported prevalence rates of XDR-TB of total MDR cases are; 6.6% overall worldwide, 6.5% in industrialized countries, 13.6% in Russia and Eastern Europe, 1.5% in Asia, 0.6% in Africa and Middle East and 15.4% in Republic of Korea. Better management and control of tuberculosis specially drug resistant TB by experienced and qualified doctors, access to standard microbiology laboratory,co-morbitidy of HIV and tuberculosis,new anti-TB drug regimens, better diagnostic tests,international standards for second line drugs (SLD)-susceptibility testing,invention of newer anti- tubercular molecules and vaccines and knowing the real magnitude of XDR-TB are some of the important issues to be addressed for effective prevention and management of XDR-TB. | en_US |
dc.description.affiliation | Post Graduate Department of Microbiology, CSM Medical University, Lucknow 226 003, India. amita602002@yahoo.com | en_US |
dc.identifier.citation | Jain A, Dixit P. Multidrug-resistant to extensively drug resistant tuberculosis: what is next? Journal of Biosciences. 2008 Nov; 33(4): 605-16 | en_US |
dc.identifier.uri | https://imsear.searo.who.int/handle/123456789/110970 | |
dc.language.iso | eng | en_US |
dc.source.uri | https://www.ias.ac.in/jbiosci/index.html | en_US |
dc.subject.mesh | Acquired Immunodeficiency Syndrome --complications | en_US |
dc.subject.mesh | Antibiotics, Antitubercular --pharmacology | en_US |
dc.subject.mesh | Drug Resistance, Multiple, Bacterial | en_US |
dc.subject.mesh | HIV Infections --complications | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Microbial Sensitivity Tests | en_US |
dc.subject.mesh | Mycobacterium tuberculosis --drug effects | en_US |
dc.subject.mesh | Treatment Outcome | en_US |
dc.subject.mesh | Tuberculosis --complications | en_US |
dc.title | Multidrug-resistant to extensively drug resistant tuberculosis: what is next? | en_US |
dc.type | Journal Article | en_US |
dc.type | Review | en_US |
Files
License bundle
1 - 1 of 1